AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03263156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and behavioural intervention
Description: The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 3 doses
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Fludarabine 25mg/m2 3 days
Description: 25 mg/m2 i.v. daily for 3 days
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide 250 mg/m2; 3 days
Description: 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Tecartus
Description: TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Abecma, Intravenous Suspension
Description: Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide 900 mg/m2; 1 day
Description: Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Breyanzi Injectable Product
Description: Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
Study NCT03967587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosense Umbilical Catheter
Description: The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
Study NCT03370731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adenotonsillectomy
Description: Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
Study NCT03370731 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nonsurgical management
Description: Nasal Irrigation or inhaled corticosteroids, etc.
Study NCT03044041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: IA (intra-articular) tranexamic acid after capsule closure
Study NCT04324450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Battery of neuropsychological tests
Study NCT03044041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IA (intra-articular) tranexamic acid after capsule closure
Study NCT02996760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Factor, Platelet-Derived
Description: 0,5 mL, vaginal use , 3 dose number
Study NCT03439852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light-to-Moderate Physical Activity / Sedentary Time
Description: 12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
Study NCT02616081 — intervention group
Intervention type: OTHER
Intervention: Indwelling Catheter
Description: Indwelling catheterization is a standard of care.
Study NCT00335049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: progressive addition spectacle lens (bifocal)
Description: Progressive addition lenses (PAL) with a +2.00 D add.
Study NCT00335049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Description: Single vision spectacle lenses.
Study NCT02740231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTA-004 intra-articular injection
Description: Each patient will undergo a single injection of JTA-004 into the knee joint
Study NCT02740231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference product intra-articular injection
Description: Each patient will undergo a single injection of Reference product into the knee joint
Study NCT05328271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Aminoisobutyric Acid
Description: All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
Study NCT05328271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-Aminoisobutyric Acid
Description: All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
Study NCT05328271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beta-Aminoisobutyric Acid
Description: All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
Study NCT01204359 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Iodine 131
Description: iodine 131，185、370、555mBq，6 months
Study NCT01277614 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic lifestyle
Description: This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
Study NCT01277614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle
Description: This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
Study NCT03220100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Palliative Care
Description: Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
Study NCT00879749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 micrograms Nexvax2
Description: 9 micrograms, weekly intra-dermal injection, 3 week duration
Study NCT00879749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 micrograms Nexvax2
Description: 30 micrograms, weekly intra-dermal injection, 3 week duration
Study NCT00879749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 micrograms Nexvax2
Description: 90 micrograms, weekly intra-dermal injection, 3 week duration
Study NCT00879749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 micrograms Nexvax2
Description: 60 micrograms, weekly intra-dermal injection, 3 week duration
Study NCT00879749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Up to 900 micrograms Nexvax2
Description: Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
Study NCT00879749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 microlitres 0.9% sterile sodium chloride for injection
Study NCT00290810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00739739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0299685 at 15mg BID
Description: 5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
Study NCT00739739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0299685 at 30mg BID
Description: 10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
Study NCT00739739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for PD 0299685
Description: Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
Study NCT03921580 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Canned Tuna
Description: 210 g/day
Study NCT03921580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Canned Tuna Variety 1
Description: 210 g/day
Study NCT03921580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Canned Tuna Variety 2
Description: 210 g/day
Study NCT02584465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen: 40 mg/day
Study NCT02584465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Stivarga; 120mg/day
Study NCT03830086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
Study NCT03830086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sufentanil
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
Study NCT03830086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
Study NCT03830086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
Study NCT01330641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Subacromial Bursa
Description: Injection of steroid and anesthetic to relieve pain
Study NCT03903744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioneuroablation
Description: The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
Study NCT03830086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
Study NCT01847820 — intervention group
Intervention type: DEVICE
Intervention: AmniSure ROM test
Description: Comparison of AmniSure ROM test to clinical diagnosis of ROM.
Study NCT01835379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oasis
Description: Oasis Ultra will be applied once per week for up to 12 weeks.
Study NCT01835379 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Study NCT03776721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction is performed on the abdomen or thighs.
Study NCT03776721 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liposuction
Description: Liposuction is performed on the abdomen or thighs.
Study NCT03776721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft
Description: 30mL harvested lipoaspirate is injected at the affected axillary site.
Study NCT03776721 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham graf (Saline injection)
Description: 30mL saline is injected at the affected axillary site.
Study NCT03776721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell injection
Description: 4mL stem cell suspension injected at the affected axillary site.
Study NCT03776721 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: 4mL saline injected at the affected axillary site.
Study NCT03045159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Families Strong Forces
Description: Parenting program
Study NCT03045159 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strong Parents
Description: self-care program
Study NCT01401049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol
Description: To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
Study NCT01401049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol/Lidocaine
Description: We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
Study NCT03370874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
Study NCT03370874 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle sheet
Description: Application of Vehicle sheet to diabetic foot ulcer
Study NCT03535675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Plus
Description: Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
Study NCT03535675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
Study NCT01884662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual walking
Description: As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking.
Study NCT01884662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wheeling tape
Description: This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
Study NCT01409590 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise program
Description: Homogenous exercise program in local fitness centers
Study NCT01409590 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Weigh loss diet program prescribed by a professional nutritionist
Study NCT02616081 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: Bladder surgery is a standard of care.
Study NCT02616081 — intervention group
Intervention type: OTHER
Intervention: Voiding
Description: Voiding spontaneously is a standard of care.
Study NCT01626521 — intervention group
Intervention type: OTHER
Intervention: CT pulmonary angio, blood tests
Description: CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
Study NCT04813315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kendall exercise
Description: consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
Study NCT04813315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's mobilization
Description: it is combination of glide along the facet joint and concurrent movement of cervical spine
Study NCT03863093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Medical Systems AIRFLOW®
Description: An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
Study NCT03863093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Medical Systems Piezo
Description: Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
Study NCT03863093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electro Medical Systems Piezo
Description: Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
Study NCT01227759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug containing the active ingredient
Description: The topical application is performed once daily during a 12-day treatment.
Study NCT01227759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing no active ingredient
Study NCT03236285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training in the fed state
Description: High-intensity interval exercise training in the fed state
Study NCT03236285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continous exercise training in the fed state
Description: Continous exercise training in the fed state
Study NCT03236285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training in the fasting state
Description: High-intensity interval exercise training in the fasting state
Study NCT03236285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continous exercise training in the fasting state
Description: Continous exercise training in the fasting state
Study NCT02477150 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Vaccination of a zoster vaccine (Zostavax)
Study NCT02477150 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administration
Study NCT01496248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: 100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.